CENTENE CORP

Centene insider trading: executives sell 30k shares, yet company stays bullish. Learn how short‑term volatility may impact your portfolio.

Centene insider sale by Burdick Kenneth A: a routine cash‑management move with no major impact on long‑term value or price. Learn why the trade matters.

Centene insider sale: Carson Michael A’s 604 phantom‑stock units reveal executive confidence in Medicaid growth and upcoming vesting rewards for investors.

Centene insider buys signal confidence in undervalued managed‑care play; tech‑driven cost control and Medicare growth promise solid upside.

Centene insider sale: CEO Tanyá McNally sells 964 shares after a 12% monthly rise—signals leadership confidence amid rising market, ESG initiatives, and future growth prospects.

Centene insider trading: CEO and execs sell shares, but controller Pienkos holds 29,843 shares—what does this mean for investors?

Centene’s executive buying spree signals confidence amid a bearish market – explore what insider trades, Medicaid expansion, and specialty services mean for investors.

Insider buying shows Centene leadership’s confidence in its long‑term dual‑focus strategy amid policy uncertainty and earnings volatility.

Centene insider selling reveals cautious leadership amid a bearish trend—explore the implications for investors and future earnings.